Distribution Agreement

In presenting this thesis or dissertation as a partial fulfillment of the requirements for an advanced degree from Emory University, I hereby grant to Emory University and its agents the non-exclusive license to archive, make accessible, and display my thesis or dissertation in whole or in part in all forms of media, now or hereafter known, including display on the world wide web. I understand that I may select some access restrictions as part of the online submission of this thesis or dissertation. I retain all ownership rights to the copyright of the thesis or dissertation. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation.

Signature:	
Yama Afshar	Date

INFLUENCE OF SPATIAL TOPOGRAPHY OF POVERTY ON HOSPITALIZATION STATUS FOLLOWING RENAL TRANSPLANTATION

By

Yama Afshar

Master of Public Health

Department of Epidemiology

Rachel Patzer, PhD, MPH

Faculty Thesis Advisor

INFLUENCE OF SPATIAL TOPOGRAPHY OF POVERTY ON HOSPITALIZATION STATUS FOLLOWING RENAL TRANSPLANTATION

By

Yama Afshar

Bachelor of Science

University of California, Los Angeles

2010

Faculty Thesis Advisor: Rachel Patzer, PhD, MPH

An abstract of

A thesis submitted to the Faculty of the

Rollins School of Public Health of Emory University
in partial fulfillment of the requirements for the degree of

Master of Public Health in Epidemiology

2013

INFLUENCE OF SPATIAL TOPOGRAPHY OF POVERTY ON HOSPITALIZATION STATUS FOLLOWING RENAL TRANSPLANTATION

Background: Previous studies suggest that neighborhood poverty contributes to disparities among patients with End Stage Renal Disease (ESRD). It is unclear whether spatial topography of poverty across geographical regions in the United States influences hospitalization status following renal transplantation.

Methods: We examined 18,736 adult (18+), first-time, kidney-only transplant recipients from the United Network for Organ Sharing database between 2004-2005. Both adjusted and unadjusted logistic regression models were used to explore the relationship between a previously described index and whether a patient was hospitalized approximately 1.5 years (620 days) post renal transplantation. Patients missing data on the exposure (n=428)—spatial topography of poverty—or outcome (n=501)—hospitalization status—were excluded from the analysis.

Results: In multivariable models adjusted for age, race, sex, BMI, diabetes, hypertension, donor type, primary form of payment, HLA match, and serum albumin at registration, we found that the odds of hospitalization among patients living in counties with high poverty rates that were categorized as spatial outliers was 1.14 (95% CI 1.01-1.28, p = 0.01) times that of patients living in counties with poverty rates within 1 standard deviation of the mean county poverty rate in the United States (14.2%) that were categorized as neither spatial outliers nor part of a concentrated cluster.

Conclusions: Our analysis demonstrates that the number of hospitalizations in a county is influenced by the economic prosperity of its surrounding counties in addition to its own poverty rate.

INFLUENCE OF SPATIAL TOPOGRAPHY OF POVERTY ON HOSPITALIZATION STATUS FOLLOWING RENAL TRANSPLANTATION

Ву

Yama Afshar

Bachelor of Science

University of California, Los Angeles

2010

Faculty Thesis Advisor: Rachel Patzer, PhD, MPH

A thesis submitted to the Faculty of the

Rollins School of Public Health of Emory University
in partial fulfillment of the requirements for the degree of

Master of Public Health in Epidemiology

2013

Table of Contents

Chapter I: Background	1
Chapter II: Manuscript	8
Title, Author, Abstract	8
Introduction	9
Methods	10
Results	13
Discussion	16
References	21
Tables	23
Figures	29
<u>Chapter III</u> : Summary, Public Health Implications, Possible Future Directions	35
Appendices	
1 10 h a 11 a 1 a 1 a 1 a 1 a 1 a 1 a 1 a 1	

Chapter I: Background

Chronic Kidney Disease (CKD) is the presence of kidney damage or decreased kidney function. The National Kidney Foundation defines CKD as an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73m² for three or more months with or without evidence of kidney damage.(1) Glomerular filtration rate (GFR)—estimated using serum creatinine with adjustments for age, race, and gender—is the volume of fluid filtered from the glomerular capillaries per unit time. As kidney function deteriorates, eGFR decreases. There are five different stages of CKD; the fifth and final stage (eGFR < 15) corresponds to end stage renal disease (ESRD) or renal failure. Adjusted five-year survival probabilities among white and black ESRD patients are just 0.32 and 0.39, respectively.(2)

One of the primary goals of Healthy People 2020—the national objectives for improving the health of all Americans—is to "reduce the incidence of CKD and its complications, disability, death, and economic costs."(3) There are 14 objectives specific to CKD alone, including a 10 percent reduction in the proportion of the US population with CKD.(3) Unfortunately, none of the objectives directly address health disparities in CKD and ESRD incidence, risk factors, and disease treatment among socioeconomic and racial groups. This chapter will provide an overview of CKD and ESRD before taking a closer look at health disparities in kidney disease.

Disease Burden

Incidence and Prevalence

CKD is a major public health problem. Between 1988-1994 and 2005-2010, the prevalence of CKD in the National Health and Nutrition Examination Survey (NHANES) population—a nationally representative sample of adults and children in the United States—increased from 12.3 to 14.0 percent, representing roughly 44 million individuals.(2) Similarly, the incidence and prevalence of end-stage renal disease (ESRD) has increased. Since 2000, the greatest adjusted incidence rates were observed in patients aged 75 and older (12.2% increase to 1,773 per million population) and blacks (7.0% decrease to 924 per million population).(2) Overall rates have remained steady in recent years. In 2010, the incidence rate fell 2.0 percent from the previous year to 348 per million population while the prevalence rose 1.7 percent to 593,086 individuals.(2)

Risk Factors

The National Kidney foundation conducted a review of longitudinal studies in order to determine risk factors associated with susceptibility, initiation, and progression of CKD.(1) Potential risk factors can be used to identify individuals at increased risk for CKD. Examples include age, gender, race, family history, diabetes, hypertension, hyperlipidemia, smoking, diet, obesity, and protein consumption.(1) Hypertension and diabetes mellitus, for instance, account for over 60% of incident ESRD.(2)

Screening

Screening individuals at high risk for CKD may prevent the incidence and progression of CKD. Both urine albumin and creatinine are noninvasive and cost-effective tests that can

be used to detect early signs of kidney damage.(2) In 2010, the probability of creatinine testing in Medicare patients was 0.77; the probability increases to 0.93 in patients with both diabetes and hypertension.(2) The probability of urine albumin testing is less common. In 2010, the probability of testing all patients was just 10%, although the probability of testing patients with both diabetes and hypertension was 36%.(2)

Treatment

Treatment of ESRD typically requires renal replacement therapy in the form of dialysis or renal transplantation. There are two types of dialysis: peritoneal dialysis and hemodialysis. They primarily differ in the location of filtration: peritoneal dialysis occurs in the body and hemodialysis occurs in a dialyzer. While patient survival is similar for both modalities, hemodialysis may be associated with lower quality of life. (4, 5) As clinical outcomes improved in the 1980s, renal transplantation surpassed maintenance dialysis as the preferred treatment modality for ESRD.(6) A review of 110 studies found that transplantation is associated with lower mortality and improved quality of life compared with dialysis. (7) Moreover, despite high initial costs, long-term costs of transplantation are less than that of dialysis: in 2010, total Medicare expenditures per person per year for dialysis patients was nearly five times that of transplant patients. (3, 8) Unfortunately, there is a shortage of kidneys available for transplant. The gap between the number of patients waiting for a transplant and the number of patients receiving a transplant continues to increase.(9) There are two main forms of renal transplantation: deceased donor and living donor. The use of kidneys from live donors is preferred as living donor

transplantation is associated with increased survival.(9) Therefore, expansion of living donor transplantation is a priority.

In 1972, Congress extended Medicare coverage to the vast majority of individuals with ESRD to ensure equitable access to renal replacement therapy. Nevertheless, disparities in access to transplantation among racial and socioeconomic groups persist. In 1985, black Medicare beneficiaries with ESRD received transplants at half the rate of white beneficiaries.(6) The same difference existed fifteen years later. In 2010, 9.0% of black ESRD patients received a kidney transplant within 3 years of initiation compared to 20.4% of whites.(2) Moreover, although blacks comprise approximately 50% of prevalent ESRD patients, they received just 33% of deceased donor transplants and 14% of living donor transplants in the same year.(2) This discrepancy in transplant rates by race is cause for concern. Living donor transplants are associated with reduced morbidity and mortality compared to deceased donor transplants; nearly twice as many living donor transplant recipients survive and maintain graft function for at least ten years (82% vs. 44%).(2)

Racial disparities also exist in the process leading to transplantation. Studies have documented the existence of racial and socioeconomic disparities in referral to a transplant center, evaluation for transplant suitability, and placement on the United Network for Organ Sharing (UNOS) deceased donor waiting list. An analysis of 2,291 black and white patients in the Southeastern United States found that a greater proportion of white versus black patients proceeded in starting the evaluation, wait listing, and

receiving a transplant.(10) As a result, improving access to healthcare may reduce some of the racial disparities observed in kidney transplantation.

Costs

Unfortunately, the aforementioned treatment modalities are costly: total Medicare expenditures per person per year in 2010 was \$87,561 for hemodialysis patients, \$66,751 for peritoneal dialysis patients, and \$32,914 for transplant patients.(2) In general, patients with ESRD consume a disproportionate amount of health care resources. Only 1.3% of Medicare patients have ESRD but they account for 7.5% of Medicare spending.(2) Economic costs only partially capture the full burden, as individuals with renal failure experience chronic disability, premature mortality, and diminished quality of life.(11)

Renal Transplant Outcomes

Renal transplant outcomes such as mortality, all-cause graft failure, and return to dialysis or retransplant have improved considerably over time. In 2010, the total death rate for persons with functioning kidney transplants decreased 2.2% from 2000 to 32.3 deaths per 1,000 patient years at risk.(2) The leading causes of death were cardiovascular disease (29.9%), infection (20.8%) and malignancy (9.4%).(2) Moreover, In 1968, only 38.8% of deceased donor transplant recipients survived and had a functioning graft two years after renal transplantation.(12) Today, over 80% of living donor transplant recipients and 44% of deceased donor transplant recipients survive and maintain graft function for at least ten years.(2) Many patients with graft failure resume dialysis and relist for repeat transplantation,

increasing the demand for donations. Approximately 4.8% of dialysis patients and 14% of patients on the kidney wait list had a failed transplant.(2, 13) Nevertheless, the probability of a return to dialysis or retransplant has decreased. Between 1991 and 2000, the aforementioned probability among deceased donor transplant recipients and living donor transplant recipients decreased by 26 and 23 percent, respectively.(13)

Racial and SES Disparities

In 2010, 46.2 million Americans lived at or below the poverty rate. Poverty or low socioeconomic status (SES) disproportionately affects minorities in the United States. Blacks suffer the highest poverty level at 27.4%. Low socioeconomic status (SES) is associated with both individual and community level factors that affect the incidence and progression of poor health outcomes, including CKD and ESRD.(14) The prevalence of CKD among blacks and whites is similar.(2) However, even after a 7.0% decrease since the previous year, the rate of ESRD among blacks was 3.4 times greater than that among whites in 2010 (262 per million population).(2) Despite comparable prevalence of CKD, the risk of ESRD for blacks is higher. The reasons for this pattern are unclear. Moreover, adjusted incidence rates of ESRD caused by diabetes vary widely by race and ethnicity. Among whites aged 30 to 39, the incident rate was 35.4 per million population, a 1.0 percent decrease from 2000.(2) For blacks of the same age, the incident rate was 133.8 per million population, a 69 percent increase from 2000.(2) A similar pattern was observed for adjusted incident rates of ESRD caused by hypertension.

Geographic variation in incidence

There is also substantial variation in the incidence of ESRD between and within different countries(2, 11, 15, 16). In 2010, the reported incidence rate was highest in Mexico (425 per million population), followed by the United States (369 per million population) and Taiwan (361 per million population).(2) On the other end of the spectrum, Bangladesh (20 per million population), Russia (40 per million population), Scotland (81 per million population), and Denmark (99 per million population) all reported incidence rates below 100 per million population.(2) In the United States, incidence rates and prevalence counts are highest in the Ohio Valley, portions of Texas and California, and the Southwestern states.(2) This geographic variation in risk reflects socioeconomic factors: Young et al. found an inverse association between the incidence of ESRD and income level.(17)

Spatial Topography of Poverty

The purpose of this study is to determine the association between a novel measure of poverty, the spatial topography of poverty, and hospitalization post renal transplantation. Spatial topography differs from mere descriptive epidemiology in the use of Moran's I to measure spatial autocorrelation, which refers to "the degree to which attributes or values at some place on the earth's surface are similar to attributes or values of nearby locations."(18) Therefore, spatial autocorrelation allows us to identify county-level "clusters" and "outliers" of poverty. We will then examine the influence of this geographical variation in the intensity of poverty on the incidence of hospitalization among adult, first-time, kidney-only transplant recipients by county.

Chapter II: Manuscript

Title, Author, Abstract

INFLUENCE OF SPATIAL TOPOGRAPHY OF POVERTY ON HOSPITALIZATION STATUS FOLLOWING RENAL TRANSPLANTATION

Author: Yama Afshar

Background: Previous studies suggest that neighborhood poverty contributes to disparities among patients with End Stage Renal Disease (ESRD). It is unclear whether spatial topography of poverty across geographical regions in the United States influences hospitalization status following renal transplantation.

Methods: We examined 18,736 adult (18+), first-time, kidney-only transplant recipients from the United Network for Organ Sharing database between 2004-2005. Both adjusted and unadjusted logistic regression models were used to explore the relationship between a previously described index and whether a patient was hospitalized approximately 1.5 years (620 days) post renal transplantation. Patients missing data on the exposure (n=428)—spatial topography of poverty—or outcome (n=501)—hospitalization status—were excluded from the analysis.

Results: In multivariable models adjusted for age, race, sex, BMI, diabetes, hypertension, donor type, primary form of payment, HLA match, and serum albumin at registration, we found that the odds of hospitalization among patients living in counties with high poverty rates that were categorized as spatial outliers was 1.14 (95% CI 1.01-1.28, p = 0.01) times that of patients living in counties with poverty rates within 1 standard deviation of the mean county poverty rate in the United States (14.2%) that were categorized as neither spatial outliers nor part of a concentrated cluster.

Conclusions: Our analysis demonstrates that the number of hospitalizations in a county is influenced by the economic prosperity of its surrounding counties in addition to its own poverty rate.

Introduction

Chronic Kidney Disease (CKD) is the presence of kidney damage or decreased kidney function. Between 1988-1994 and 2005-2010, the prevalence of CKD in the National Health and Nutrition Examination Survey (NHANES) population—a nationally representative sample of adults and children in the United States—increased from 12.3 to 14.0 percent, representing roughly 44 million individuals.(2) There are five different stages of CKD; the fifth and final stage (eGFR < 15) corresponds to end stage renal disease (ESRD) or renal failure. Adjusted five-year survival probabilities among white and black ESRD patients are just 0.32 and 0.39, respectively.(2)

In the United States, health disparities persist in CKD and ESRD incidence, risk factors, and disease treatment. Low socioeconomic status (SES) and race in particular are associated with individual and community level factors that affect the incidence and progression of poor health outcomes.(14) Although the prevalence of CKD among blacks and whites is similar, the rate of ESRD among blacks was 3.4 times greater than that among whites in 2010.(2) The reasons for this pattern are unclear.

Neighborhood poverty has been shown in previous studies to contribute to disparities in access to treatment among ESRD patients.(19-21) However, it is unclear whether the

influence of contextual-level poverty extends to hospitalization following kidney transplantation. Nevertheless, a higher hospitalization rate in transplant recipients was observed among minorities vs. whites in a study of 32961 Medicare primary kidney transplant recipients.(22)

The purpose of this study is to examine the influence of a novel measure of neighborhood poverty—the spatial topography of poverty—on hospitalization following renal transplantation among a cohort of transplant recipients in the United States (US).

Methods

Study Population and Data Sources

The United Network for Organ Sharing (UNOS) is a non-profit organization that maintains the Organ Procurement and Transplantation Network (OPTN) Database.

OPTN contains information regarding every organ donation and transplant event in the US since October 1, 1987. For this study, we used the Standard Transplant Analysis and Research (STAR) files based on OPTN data for kidney, pancreas, and kidney-pancreas waiting list and transplant/follow up patients between October 1, 1987 and October 31, 2011. STAR data was linked to the SAS ZIP code data file by ZIP code at transplantation, which was subsequently linked to a previously described index(18) by the counties' five-digit Federal Information Processing Standard (FIPS) code. The index contains a novel measure of community-level poverty, the spatial topography of poverty.

We restricted our analyses to data from 6/30/2004 to 1/1/2007 for adult (18 years or older), first-time, kidney-only transplant recipients where the transplant was received

before 1/1/2006, based on the availability of UNOS hospitalization data (Table 1). Analyses were further restricted by excluding those with missing information on both the exposure—spatial topography of poverty (n = 428)—and outcome (n = 501)—number of hospitalizations within a year and a half following renal transplantation. Patients who died or were lost to follow-up during the study period (n= 455) were similarly excluded Unreasonable values for body mass index (less than 10 and greater than 100) (n=231) and eGFR (greater than 125) were set to missing (n=2). The patients who were excluded for missing data on exposure or outcome were compared with those who were included in this analysis and found to be similar. Therefore, we believe that these data are missing at random.

Primary Exposure

The primary exposure was a novel measure of community-level poverty with a spatial component described by Dr. James Holt.(18) Using Census data from 2000, the poverty rate for each county was compared with the overall mean poverty rate for the United States (14.2%). Counties with a poverty rate greater than 1 standard deviation above the mean poverty rate were categorized as "high" poverty counties. On the other end of the spectrum, counties with a poverty rate less than 1 standard deviation below the mean poverty rate were categorized as "low" poverty counties. In order to measure spatial autocorrelation, local Moran indices were calculated for each county and converted to z scores.(18) A local Moran's z score greater than or equal to 2 indicates that the county was located in a concentrated cluster; a z score less than or equal to -2 indicates that the county was a spatial outlier; and a z score between -2.0 and 2.0 is neither.(18) The

poverty levels and spatial situations were combined in order to create four distinct categories. A fifth category, "other," included counties with a poverty rate within 1 standard deviation of the mean poverty rate and belonged to neither a spatial concentration nor spatial outlier.

Primary Outcome

The primary outcome for this study was hospitalization status (yes vs. no) in approximately 1.5 years (620 days) post renal transplantation. Only hospitalizations experienced after the transplant visit were considered for these analyses.

Statistical Analyses

We performed descriptive analyses on the spatial topography of poverty, number of hospitalizations, and several potential confounders including recipient characteristics, comorbidities, socioeconomic status, donor characteristics, and transplant characteristics. Covariates under consideration included age; race; sex; BMI (kg/m²); education level (none, grade school, high school, attended college, associate/bachelor degree, post-college graduate degree, missing); HLA match level (zero-six, missing); serum albumin (<=3.5, >3.5 g/dL, missing); diabetes (yes, no, missing); hypertension (yes, no, missing); primary form of payment (private insurance, public insurance, missing); donor type (living, deceased, deceased-expanded criteria); cold ischemia time (0-10, 11-20, 21-30, >30 hours, missing); and an interaction term between race and spatial topography of poverty. Multiple logistic regression models were developed, beginning with an unadjusted analysis of hospitalization status by spatial topography of poverty. Variables

that were found to be associated with both exposure and outcome during descriptive analyses were included in the preliminary multivariable ("gold standard") model. A stepwise backwards elimination procedure, described by Kleinbaum,(23) was used in the determination of the final model (Table 3). The least significant (highest p-value above α) covariate was dropped from the gold standard. This process was repeated until only statistically significant covariates remained. We assessed confounding and precision by comparing the odds ratios (OR) and confidence interval (CI) width in the model resulting from backwards elimination to the gold standard OR, respectively. The final model adjusted for age, race, sex, BMI, diabetes, hypertension, donor type, primary form of payment, HLA match, and serum albumin at registration. The absence of multicollinearly was confirmed.

Statistical Significance

All tests were two-sided, with statistical significance set at the $\alpha = 0.05$ level. Analyses were conducted using SAS 9.3 (North Carolina).

Results

A total of 18,736 adult, first-time, kidney-only transplant recipients were identified who met the inclusion criteria for this analysis. The mean age of the study population was 50 years (±14), 3,799 (25%) were black, 11,251 were men (60%), and the majority of patients had body mass indices greater than 24.9 kg/m² with 5,548 (30%) overweight, 4,468 (24%) obese, and 360 (2%) morbidly obese.

The characteristics of these subjects stratified by spatial topography of poverty and hospitalization status are presented in Table 1 and Table 2, respectively. Approximately 41% of the sample lived in low poverty counties, 18% lived in high poverty counties, and 41% lived in counties within 1 standard deviation of the mean poverty rate for the United States ("Other"). Compared to white patients, black patients were more likely to live in high poverty counties regardless of spatial status (30% black vs. 11% white, p < 0.001). The difference was even greater for high poverty counties classified as spatial outliers (16% black vs. 4% white, p < 0.001) (Figures 3 and 4). Moreover, while the distributions of sex was similar across categories of spatial topography of poverty; race, age, BMI, donor type, HLA match level, total serum albumin, cold ischemia time, diabetes, hypertension, education level, and primary form of payment were associated with spatial topography of poverty (p < 0.001 for all comparisons).

Roughly 40% of patients were hospitalized within 1.5 years post renal transplantation. Blacks were significantly more likely to be hospitalized than whites (43% black vs. 39% white, p < 0.001). Age, race, BMI, donor type, HLA match level, total serum albumin, diabetes, hypertension and primary form of payment were all significantly associated with hospitalization status (p < 0.001 for all comparisons). Sex (p = 0.02) and education (p = 0.03) were also significantly associated with hospitalization status.

Figure 1 shows the proportion of hospitalizations by spatial topography of poverty. Among low poverty counties, a higher proportion of patients living in clusters were hospitalized compared to patients living in outliers (40.7% cluster vs. 38.6%, p = 0.17).

This difference was not statistically significant. However, among high poverty counties, there was a statistically significant increase in the proportion of hospitalizations in outlier counties compared to counties belonging to a cluster (43.5% outlier vs. 39.1% cluster, p = 0.01).

In unadjusted logistic regression of hospitalization status by spatial topography of poverty found, the odds of hospitalization was 1.26 (95% CI 1.13, 1.41) times higher among patients living in high poverty outlier counties and 1.13 (1.05, 1.20) times higher among patients living in low poverty cluster counties compared to patients living in counties that neither belong to a spatial category nor have a poverty rate within 1 standard deviation of the mean for the United States ("Other"). However, the odds of hospitalization among patients living in high poverty cluster counties (OR 1.05, 195% CI 0.95-1.17) and low poverty outlier counties (OR 1.03, 0.91-1.17) were not significantly different from patients living in the previously described other category.

Following adjustment for potential confounders, the odds of hospitalization among patients living in high poverty cluster counties was 1.14 times higher than patients living in the "Other" category (95% CI 1.04-1.42). Significant associations between covariates and hospitalization status were also observed. For instance, the odds of hospitalization among patients with diabetes and hypertension was 1.3 (95% CI 1.22–1.39) and 1.4 (1.05-1.24) times that of patients without diabetes or hypertension, respectively. Moreover, the odds of hospitalization among extended criteria deceased donor transplant recipients was 1.53 (95% CI 1.37-1.71) times that of patients who received a living donor

transplant. There was no statistically significant difference in the odds of hospitalization between black and white (1.06, 95% CI 0.98-1.15) patients. In multivariable analyses, we did not observe interaction between race and spatial topography of poverty. In other words, their joint effect did not significantly differ from their independent effects (p = 0.73)

Discussion

In this analysis, we examined the effect of spatial topography of poverty on hospitalization status following renal transplantation. Patients living in counties with high poverty rates that were categorized as spatial outliers and counties with low poverty rates belonging to a concentrated cluster had significantly higher odds of hospitalization 1.5 years post renal transplantation compared to patients living in counties with poverty rates within 1 standard deviation of the mean county poverty rate in the United States (14.2%) that were categorized as neither spatial outliers nor part of a concentrated cluster. These differences were observed in crude analyses and after adjustment in multivariable models. Patients living in counties with high poverty rates belonging to a concentrated cluster and counties with low poverty rates that were categorized as spatial outliers had similar odds as the aforementioned referent group. Therefore, while neighborhood poverty has been shown to contribute to disparities in ESRD, our analysis demonstrates that the number of hospitalizations in a county is also influenced by the economic prosperity of its surrounding counties. The reasons for this association are unclear.

Hospitalizations are an important proxy for poor health outcomes post renal transplantation, such as mortality and loss of graft function. Our finding that

neighborhood poverty is associated with poor health outcomes is supported by a number of earlier studies. For instance, in a study of graft failure and graft function after transplantation, Press *et al.* found a lower incidence of graft survival among transplant recipients living in the poorest level of zip code poverty (173/1000 persons years) compared to the richest level (125/1000 person years).(24) Furthermore, a review of sociocultural and socioeconomic disparities in kidney transplant outcomes found consistent evidence of worse outcomes for patients with low income, less education, and black patients.(25) Although the proportion of blacks versus whites hospitalized in our study was greater for every category of spatial topography of poverty except the other category, we did not find a statistically significant association between black race and hospitalization in our adjusted multivariable model. There was also no association between patient education level and hospitalization.

Our findings also contribute to the growing body of disparities research in CKD and ESRD. Several studies have examined the association between race, poverty, and access to renal transplantation. Volkova *et al.* found a strong association between neighborhood poverty and ESRD incidence in both blacks and whites.(20) Similarly, Patzer *et al.* concluded that neighborhood poverty was associated with placement on the renal transplant waitlist. Relatively few studies, however, have examined the association between race, poverty and post-transplant outcomes.

The reasons for increased hospitalization in high poverty (spatial outlier) counties and low poverty (concentrated) counties are not immediately clear. Axelrod *et al.* found that

patients living further away from transplant centers had increased risk of post-transplant death. (26) Since affluent areas are more likely to have better healthcare resources, high and low poverty counties surrounded by prosperous counties would be expected to have decreased risk of poor health outcomes post-transplant. In that regard, hospitalization may have different meaning for high and low poverty counties. For instance, affluent individuals may be more likely to seek care for less severe conditions because they have the means to do so. Impoverished individuals, on the other hand, only do so out of necessity.

Nevertheless, there are several potential social and ecological explanations for the patterns observed in this study. The Gini coefficient is one of several measures of wealth distribution. A lower coefficient corresponds to greater equality; a higher coefficient corresponds to lesser equality. Wilkinson and Pickett found that health and social problems are more common in areas with a higher Gini coefficient.(27) As a result, areas with increased wealth distribution—such as a high poverty county surrounded by low poverty counties—may have increased risk of poor health outcomes. Residential segregation is another measure that may be associated with ESRD outcomes. It refers to the manner in which two or more groups live separately from one another.(28) Kimmel et al. found that black residents living in highly segregated areas had a 13% increased mortality risk.(29) Therefore, residential segregation may help explain the influence of surrounding counties on hospital readmission post-transplant.

Strengths and Limitations

Our study had several limitations. For instance, the analysis did not account for the potential correlation of patients living within the same county. Moreover, the UNOS database contains information regarding the number of transplant related hospitalizations during follow-up between 6/30/2004 and 1/1/2007; more recent data on hospitalizations was not available, and thus we are unable to evaluate whether the association between spatial topography of poverty and hospitalization is consistent in a more recent era of increased scrutiny and regulation on hospitalization readmissions following transplantation. The index we used to characterize the geographic concentration of poverty, however, was calculated using Census data from the year 2000. Despite this discrepancy, the poverty rate in the United States was relatively constant between 2000 and 2006.(30) Our study is also limited by the lack of individual-level poverty data in the UNOS database, although we did have individual proxies of poverty with the measurement of health insurance status and patient education level. Another limitation is that we do not have information on the date of hospitalization. As a result, it's difficult to assess the effect of early versus late hospital readmission. Patients who died or were lost to follow-up during the study period were excluded. Strengths of this research include the use of a nationally-representative surveillance database that contains information regarding every organ donation and transplant event in the United States. As a result, the population is sufficiently large and racial categories are well represented.

In summary, despite near universal coverage under Medicare, discrepancies in transplant outcomes by neighborhood poverty persist. Our findings show that the number of hospitalizations in a county is also influenced by the economic prosperity of its

surrounding counties in addition to its own poverty rate. These results will aid in the identification of areas at increased risk for poor health outcomes post renal transplantation.

References

- 1. Foundation NK. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis, 2002 (suppl 1).
- 2. System URD. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
- 3. Services UDoHaH. Chronic Kidney Disease. 2012. (http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid =6). (Accessed).
- 4. Ginieri-Coccossis M, Theofilou P, Synodinou C, et al. Quality of life, mental health and health beliefs in haemodialysis and peritoneal dialysis patients: investigating differences in early and later years of current treatment. *BMC nephrology* 2008;9:14.
- 5. Vonesh EF, Snyder JJ, Foley RN, et al. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? *Kidney international Supplement* 2006(103):S3-11.
- 6. Eggers PW. Effect of transplantation on the Medicare end-stage renal disease program. *The New England journal of medicine* 1988;318(4):223-9.
- 7. Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2011;11(10):2093-109.
- 8. Kasiske BL, Cohen D, Lucey MR, et al. Payment for immunosuppression after organ transplantation. American Society of Transplantation. *JAMA* 2000;283(18):2445-50.
- 9. Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999-2008. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2010;10(4 Pt 2):961-72.
- 10. Patzer RE, Perryman JP, Schrager JD, et al. The Role of Race and Poverty on Steps to Kidney Transplantation in the Southeastern United States. *American Journal of Transplantation* 2012;12(2):358-68.
- 11. McClellan WM. Epidemiology and risk factors for chronic kidney disease. *The Medical clinics of North America* 2005;89(3):419-45.
- 12. Friedman EA, Delano BG, Butt KMH. Pragmatic Realities in Uremia Therapy. *New England Journal of Medicine* 1978;298(7):368-71.
- 13. Marcen R, Teruel JL. Patient outcomes after kidney allograft loss. *Transplantation reviews (Orlando, Fla)* 2008;22(1):62-72.
- 14. Young BA. The interaction of race, poverty, and CKD. *American journal of kidney diseases: the official journal of the National Kidney Foundation* 2010;55(6):977-80.

- 15. Usami T KKTOMKKG. REgional variations in the incidence of end-stage renal failure in japan. *JAMA* 2000;284(20):2622-4.
- 16. Foxman B, Moulton LH, Wolfe RA, et al. Geographic variation in the incidence of treated end-stage renal disease. *Journal of the American Society of Nephrology* 1991;2(6):1144-52.
- 17. Young EW, Mauger EA, Jiang KH, et al. Socioeconomic status and end-stage renal disease in the United States. *Kidney international* 1994;45(3):907-11.
- 18. JB H. The topography of poverty in the United States: a spatial analysis using county-level data from the Community Health Status Indicators project. . *Prev Chronic Dis* 2007;4(4).
- 19. McClellan WM, Newsome BB, McClure LA, et al. Poverty and racial disparities in kidney disease: the REGARDS study. *American journal of nephrology* 2010;32(1):38-46.
- 20. Volkova N, McClellan W, Klein M, et al. Neighborhood poverty and racial differences in ESRD incidence. *Journal of the American Society of Nephrology : JASN* 2008;19(2):356-64.
- 21. Patzer RE, Amaral S, Wasse H, et al. Neighborhood poverty and racial disparities in kidney transplant waitlisting. *Journal of the American Society of Nephrology : JASN* 2009;20(6):1333-40.
- 22. McAdams-Demarco MA, Grams ME, Hall EC, et al. Early hospital readmission after kidney transplantation: patient and center-level associations. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2012;12(12):3283-8.
- 23. Kleinbaum DG, Klein M, Pryor ER. *Logistic Regression: A Self-Learning Text*. Springer; 2010.
- 24. Press R, Carrasquillo O, Nickolas T, et al. Race/ethnicity, poverty status, and renal transplant outcomes. *Transplantation* 2005;80(7):917-24.
- 25. Gordon EJ, Ladner DP, Caicedo JC, et al. Disparities in kidney transplant outcomes: a review. *Seminars in nephrology* 2010;30(1):81-9.
- 26. Axelrod DA, Dzebisashvili N, Schnitzler MA, et al. The Interplay of Socioeconomic Status, Distance to Center, and Interdonor Service Area Travel on Kidney Transplant Access and Outcomes. *Clinical Journal of the American Society of Nephrology* 2010;5(12):2276-88.
- 27. Wilkinson RG PK. *The Spirit Level: Why Greater Equality Makes Societies Stronger*. London: Bloomsbury Press; 2010.
- 28. Massey DS, Denton NA. The Dimensions of Residential Segregation. *Social Forces* 1988;67(2):281-315.
- 29. Kimmel PL, Fwu CW, Eggers PW. Segregation, income disparities, and survival in hemodialysis patients. *Journal of the American Society of Nephrology : JASN* 2013;24(2):293-301.
- 30. Bureau USC. Current Population Survey, 1960 to 2012 Annual Social and Economic Supplements.

Tables

Table 1. Baseline Demographics of Study Population by Spatial Topography of Poverty - United Network for Organ Sharing (2004-2007)

					Spatia	l Topogra	aphy of F	overty					
	O	verall	Low C	luster	Low C	Outlier	High C	luster	High (Outlier	Otl	her	
	N	%	N	%	N	%	N	%	N	%	N	%	P-
													value
	18,	100.00	6,564	35.03	1,145	6.11	1,836	9.80	1,446	7.72	7,745	41.34	
	736												
Ethnicity													<.001
White	10,	55.31	4,714	71.82	723	63.14	686	37.36	421	29.11	3,819	49.31	
	363												
Black	4,6	24.72	1,158	17.64	288	25.15	626	34.10	760	52.56	1,800	23.24	
	32												
Hispanic	2,4	12.89	364	5.55	93	8.12	446	24.29	180	12.45	1,333	17.21	
	16												
Asian	943	5.03	265	4.04	34	2.97	18	0.98	49	3.39	577	7.45	
Amer Ind/Alaska Native	169	0.90	30	0.46	-	-	47	2.56	21	1.45	71	0.92	
Native Hawaiian/other	89	0.48	11	0.17	1	0.09	3	0.16	-	-	74	0.96	
Pacific Islander													
Multiracial	124	0.66	22	0.34	6	0.52	10	0.54	15	1.04	71	0.92	
Gender													0.52
M	11,	60.05	3,966	60.42	690	60.26	1,120	61.00	842	58.23	4,633	59.82	
	251												
Age													<.001
<30	1,7	9.46	575	8.76	94	8.21	184	10.02	138	9.54	781	10.08	
	72												
30 to 39	2,7	14.58	886	13.50	161	14.06	268	14.60	209	14.45	1,207	15.58	
	31												
40 to 49	4,1	22.10	1,497	22.81	242	21.14	434	23.64	312	21.58	1,656	21.38	
	41												
50 to 59	5,2	28.20	1,846	28.12	320	27.95	544	29.63	401	27.73	2,173	28.06	

	84												
60 to 69	3,7	20.26	1,359	20.70	258	22.53	348	18.95	312	21.58	1,518	19.60	
. 70	95	Г 41	401	C 11	70	C 11	Ε0	2.16	7.4	F 12	410	F 20	
>=70	1,0 13	5.41	401	6.11	70	6.11	58	3.16	74	5.12	410	5.29	
BMI*	15												<.001
<18.5	480	2.56	155	2.36	30	2.62	38	2.07	37	2.56	220	2.84	<.001
18.5 to 24.9	5,5	29.66	1,910	29.10	332	29.00	503	27.40	453	31.33	2,360	30.47	
10.5 to 24.5	58	23.00	1,310	23.10	332	23.00	303	27.40	433	31.33	2,300	30.47	
25 to 29.9	5,5	29.61	1,963	29.91	349	30.48	518	28.21	419	28.98	2,299	29.68	
	48		,								,		
30 to 39.9	4,4	23.85	1,668	25.41	256	22.36	487	26.53	338	23.37	1,719	22.19	
	68												
>=40	360	1.92	165	2.51	20	1.75	32	1.74	32	2.21	111	1.43	
Missing	2,3	12.39	703	10.71	158	13.80	258	14.05	167	11.55	1,036	13.38	
	22												
Donor Type													<.001
Living	8,0	43.16	3,301	50.29	452	39.48	627	34.15	529	36.58	3,177	41.02	
	86												
Deceased	8,7	46.85	2,635	40.14	578	50.48	1,035	56.37	721	49.86	3,809	49.18	
Funandad Critaria	78 1.8	0.00	628	0.57	115	10.04	174	9.48	196	12 55	750	9.80	
Expanded Criteria	1,8 72	9.99	028	9.57	115	10.04	1/4	9.48	196	13.55	759	9.80	
HLA Match Level**	12												<.001
Zero	3,2	17.53	1,071	16.32	207	18.08	307	16.72	315	21.78	1,385	17.88	1.001
2010	85	17.55	1,071	10.52	207	10.00	307	10.72	313	21.70	1,303	17.00	
One	5,0	27.03	1,671	25.46	297	25.94	528	28.76	442	30.57	2,126	27.45	
	64		,								,		
Two	3,2	17.29	1,128	17.18	203	17.73	324	17.65	234	16.18	1,351	17.44	
	40												
Three	3,8	20.34	1,448	22.06	235	20.52	348	18.95	244	16.87	1,535	19.82	
	10												
Four	1,3	7.32	504	7.68	95	8.30	131	7.14	96	6.64	546	7.05	
	72								_				
Five	1,0	5.37	357	5.44	57	4.98	99	5.39	64	4.43	429	5.54	

	06												
Six	893	4.77	367	5.59	48	4.19	80	4.36	48	3.32	350	4.52	
Missing	66	0.35	18	0.27	3	0.26	19	1.03	3	0.21	23	0.30	
Total Serum Albumin													<.001
<=3.5	3,2 37	17.28	1,110	16.91	209	18.25	365	19.88	207	14.32	1,346	17.38	
>3.5	10,	55.70	3,612	55.03	743	64.89	1,135	61.82	835	57.75	4,111	53.08	
	436		,				,				,		
Missing	5,0 63	27.02	1,842	28.06	193	16.86	336	18.30	404	27.94	2,288	29.54	
Cold Ischemia Time													<.001
0-10	6,4 87	34.62	2,584	39.37	349	30.48	424	23.09	448	30.98	2,682	34.63	
10-20	4,4 18	23.58	1,305	19.88	290	25.33	453	24.67	430	29.74	1,940	25.05	
20-30	2,9 18	15.57	806	12.28	237	20.70	360	19.61	207	14.32	1,308	16.89	
>30	764	4.08	220	3.35	48	4.19	84	4.58	80	5.53	332	4.29	
Missing	4,1 49	22.14	1,649	25.12	221	19.30	515	28.05	281	19.43	1,483	19.15	
Diabetes	.5												<.001
No	12, 573	67.11	4,407	67.14	816	71.27	1,201	65.41	908	62.79	5,241	67.67	
Yes	5,7 92	30.91	1,994	30.38	314	27.42	613	33.39	464	32.09	2,407	31.08	
Missing	371	1.98	163	2.48	15	1.31	22	1.20	74	5.12	97	1.25	
Hypertension													<.001
No	2,9	15.51	1,011	15.40	149	13.01	288	15.69	178	12.31	1,280	16.53	
Vac	06	70.00	F 224	70.74	026	01 75	1 170	00.20	1 120	70 77	C 10C	00.00	
Yes	14, 981	79.96	5,234	79.74	936	81.75	1,476	80.39	1,139	78.77	6,196	80.00	
Missing	849	4.53	319	4.86	60	5.24	72	3.92	129	8.92	269	3.47	
Education	043	4.55	313	4.00	00	3.24	, 2	3.52	123	0.52	209	3.47	<.001
None	110	0.59	32	0.49	5	0.44	13	0.71	7	0.48	53	0.68	

Grade School	977	5.21	193	2.94	49	4.28	161	8.77	95	6.57	479	6.18	
High School	7,2 95	38.94	2,622	39.95	450	39.30	805	43.85	611	42.25	2,807	36.24	
Attended College	3,7 86	20.21	1,255	19.12	261	22.79	383	20.86	226	15.63	1,661	21.45	
College Degree	2,4 35	13.00	994	15.14	162	14.15	180	9.80	152	10.51	947	12.23	
Graduate Degree	1,0 50	5.60	472	7.19	65	5.68	66	3.59	77	5.33	370	4.78	
Missing	3,0 83	16.45	996	15.17	153	13.36	228	12.42	278	19.23	1,428	18.44	
Primary Payment													<.001
Private Insurance	7,8 72	42.02	3,330	50.73	471	41.14	486	26.47	474	32.78	3,111	40.17	
Public Insurance	10,	57.81	3,222	49.09	671	58.60	1,345	73.26	969	67.01	4,625	59.72	
	832												
Other	832 32	0.17	12	0.18	3	0.26	5	0.27	3	0.21	9	0.12	
Other		0.17 SD	12 Mean	0.18 SD	3 Mean	0.26 SD	5 Mean	0.27 SD	3 Mean	0.21 SD	9 Mean	0.12 SD	P-
	32 Me an	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	value
Other	32 Me												-
	32 Me an 49.	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	value
Age	32 Me an 49. 58 27.	SD 13.55	Mean 50.12	SD 13.49	Mean 50.28	SD 13.51	Mean 48.65	SD 13.05	Mean 49.91	SD 13.64	Mean 49.18	SD 13.69	value <.001
Age BMI	32 Me an 49. 58 27. 38 12.	SD 13.55 5.62	Mean 50.12 27.71	SD 13.49 5.85	Mean 50.28 27.22	SD 13.51 5.44	Mean 48.65 27.73	SD 13.05 5.56	Mean 49.91 27.33	SD 13.64 5.61	Mean 49.18 27.04	SD 13.69 5.44	value <.001 <.001
Age BMI Cold Ischemic Time	32 Me an 49. 58 27. 38 12. 83 3.8	SD 13.55 5.62 10.72	Mean 50.12 27.71 11.21	SD 13.49 5.85 10.66	Mean 50.28 27.22 14.13	SD 13.51 5.44 10.77	Mean 48.65 27.73 15.28	SD 13.05 5.56 10.43	Mean 49.91 27.33 13.74	SD 13.64 5.61 10.78	Mean 49.18 27.04 13.23	SD 13.69 5.44 10.63	value <.001 <.001 <.001

^{*}Body Mass Index (kg/m²)

**Human Leukocyte Antigen Match Level

 $Table\ 2.\ Baseline\ Demographics\ of\ Study\ Population\ by\ Hospitalization\ Status\ -\ United\ Network\ for\ Organ\ Sharing\ (2004-2007)$

			Ву	lospitali	zation Sta	atus	
	Ove	erall	Y	es	N	0	
	N	%	N	%	N	%	P-
							value
Pale of the c	18,736	100.00	7,400	39.50	11,336	60.50	. 001
Ethnicity	40.262	FF 24	4.056	E 4 04	C 207	FF C4	<.001
White	10,363	55.31	4,056	54.81	6,307	55.64	
Black	4,632	24.72	2,012	27.19	2,620	23.11	
Hispanic	2,416	12.89	874	11.81	1,542	13.60	
Asian	943	5.03	315	4.26	628	5.54	
Amer Ind/Alaska Native	169	0.90	72	0.97	97	0.86	
Native Hawaiian/other	89	0.48	32	0.43	57	0.50	
Pacific Islander							
Multiracial	124	0.66	39	0.53	85	0.75	
Gender							0.018
M	11,251	60.05	4,366	59.00	6,885	60.74	
Age							0.001
<30	1,772	9.46	701	9.47	1,071	9.45	
30 to 39	2,731	14.58	1,019	13.77	1,712	15.10	
40 to 49	4,141	22.10	1,591	21.50	2,550	22.49	
50 to 59	5,284	28.20	2,094	28.30	3,190	28.14	
60 to 69	3,795	20.26	1,544	20.86	2,251	19.86	
>=70	1,013	5.41	451	6.09	562	4.96	
BMI*							<.001
<18.5	480	2.56	190	2.57	290	2.56	
18.5 to 24.9	5,558	29.66	2,171	29.34	3,387	29.88	
25 to 29.9	5,548	29.61	2,183	29.50	3,365	29.68	
30 to 39.9	4,468	23.85	1,880	25.41	2,588	22.83	
>=40	360	1.92	176	2.38	184	1.62	
Missing	2,322	12.39	800	10.81	1,522	13.43	
Donor Type							<.001
Living	8,086	43.16	2,956	39.95	5,130	45.25	
Deceased	8,778	46.85	3,525	47.64	5,253	46.34	
Expanded Criteria	1,872	9.99	919	12.42	953	8.41	
HLA Match Level**	•						<.001
Zero	3,285	17.53	1,428	19.30	1,857	16.38	
One	5,064	27.03	2,050	27.70	3,014	26.59	
Two	3,240	17.29	1,315	17.77	1,925	16.98	
Three	3,810	20.34	1,465	19.80	2,345	20.69	
Four	1,372	7.32	489	6.61	883	7.79	
Five	1,006	5.37	340	4.59	666	5.88	
Six	893	4.77	289	3.91	604	5.33	
Missing	66	0.35	24	0.32	42	0.37	
Total Serum Albumin	00	0.55	24	0.32	42	0.57	<.001
<=3.5	3,237	17.28	1,410	19.05	1,827	16.12	\.UU1
<=3.5 >3.5	10,436	55.70	4,054	54.78	6,382	56.30	
73.5 Missing	5,063				3,127	27.58	
Cold Ischemia Time	5,003	27.02	1,936	26.16	3,12/	۷/.۵۵	<.001

0-10	6,487	34.62	2,401	32.45	4,086	36.04	
10-20	4,418	23.58	1,879	25.39	2,539	22.40	
20-30	2,918	15.57	1,217	16.45	1,701	15.01	
>30	764	4.08	334	4.51	430	3.79	
Missing	4,149	22.14	1,569	21.20	2,580	22.76	
Diabetes							<.001
No	12,573	67.11	4,673	63.15	7,900	69.69	
Yes	5,792	30.91	2,559	34.58	3,233	28.52	
Missing	371	1.98	168	2.27	203	1.79	
Hypertension							<.001
No	2,906	15.51	1,051	14.20	1,855	16.36	
Yes	14,981	79.96	5,984	80.86	8,997	79.37	
Missing	849	4.53	365	4.93	484	4.27	
Education							<.001
None	110	0.59	41	0.55	69	0.61	
Grade School	977	5.21	382	5.16	595	5.25	
High School	7,295	38.94	2,980	40.27	4,315	38.06	
Attended College	3,786	20.21	1,491	20.15	2,295	20.25	
College Degree	2,435	13.00	905	12.23	1,530	13.50	
Graduate Degree	1,050	5.60	390	5.27	660	5.82	
Missing	3,083	16.45	1,211	16.36	1,872	16.51	
Primary Payment							<.001
Private Insurance	7,872	42.02	2,849	38.50	5,023	44.31	
Public Insurance	10,832	57.81	4,543	61.39	6,289	55.48	
Other	32	0.17	8	0.11	24	0.21	
	Mean	SD	Mean	SD	Mean	SD	Р-
	ivicali	30	IVICALI	30	ivicali	30	value
Age	49.58	13.55	49.97	13.70	49.33	13.45	0.002
BMI	27.38	5.62	27.62	5.81	27.22	5.49	<.001
Cold Ischemic Time	12.83	10.72	13.55	10.71	12.35	10.71	<.001
Total Serum Albumin	3.89	0.60	3.86	0.61	3.91	0.59	<.001
County Poverty	12.55	5.77	12.47	5.64	12.60	5.85	0.14
*Body Mass Index (kg/m²)							·

^{*}Body Mass Index (kg/m²)

^{**}Human Leukocyte Match Level


Table 3. Multivariable Modeling Results - Final Model

	FIN	NAL MO	DEL
	Odds Ratio	Lower 95% CI	Upper 95% CI
MAIN EFFECTS			
Spatial Topography of Poverty (Ref =			
Other)	0.99	0.89	1.10
Low poverty (concentrated)			
Low poverty (spatial outlier)	1.14 1.12	1.01 1.05	1.28
High poverty (concentrated) High poverty (spatial outlier)	0.99	0.87	1.20 1.13
COVARIATES	0.99	0.87	1.13
Race (Ref=White)			
Black	1.06	0.98	1.15
Hispanic	0.83	0.76	0.92
Asian	0.83	0.70	0.92
American Indian/Alaskan Native	0.74	0.69	1.30
Pacific Islander	0.82	0.53	1.27
Multiracial	0.68	0.33	1.00
Sex (Ref = Female)	0.00	0.10	1.00
Male	0.92	0.86	0.97
Age (Ref = <30)	0.52	0.00	0.57
30 to 39	0.85	0.75	0.97
40 to 49	0.86	0.76	0.96
50 to 59	0.85	0.76	0.96
60 to 69	0.82	0.73	0.93
>=70	0.92	0.78	1.09
BMI (Ref = <18.5)*			
18.5 to 24.9	0.98	0.81	1.19
25 to 29.9	0.96	0.79	1.17
30 to 39.9	1.03	0.85	1.25
>=40	1.29	0.97	1.70
Missing	0.77	0.63	0.95
Donor Type (Ref = Living Donor)			
Deceased	1.12	1.04	1.20
Deceased - Expanded Criteria	1.53	1.37	1.71
HLA Match Level (Ref = 0)			
One	0.89	0.81	0.97
Two	0.91	0.82	1.00
Three	0.89	0.81	0.99
Four	0.78	0.69	0.89
Five	0.70	0.61	0.82
Six	0.67	0.57	0.79
Missing	0.86	0.52	1.44
Diabetes (Ref = No)			

Yes	1.30	1.22	1.39
Missing	1.35	1.07	1.71
Hypertension (Ref = No)			
Yes	1.14	1.05	1.24
Missing	1.26	1.06	1.50
Primary Payment (Ref = Private Insurance)			
Public Insurance	1.21	1.14	1.30
Other	0.64	0.28	1.43
Serum Albumin (Ref = <= 3.5)			
> 3.5	0.84	0.77	0.91
Missing	0.80	0.73	0.88
*Body Mass Index (kg/m2)			

Figures

Figure 1. Proportion of Patients Hospitalized by Spatial Topography of Poverty



 $\label{thm:continuous} \textbf{Figure 2. Proportion of Patients Hospitalized by Spatial Topography of Poverty and Race } \\$




Figure 3. Patient Distribution by Spatial Topography of Poverty and Race: Low Poverty Categories





Figure 4. Patient Distribution by Spatial Topography of Poverty and Race: High Poverty Categories




Chapter III: Public Health Implications and Possible Future Directions

Previous studies suggest that socioeconomic status contributes to disparities among patients with End Stage Renal Disease. In this analysis, we assessed the association of a novel measure of neighborhood poverty, spatial topography of poverty, on transplant related hospitalization post renal transplant. We found that patients residing in high and low poverty counties surrounded by affluent areas are more likely to be hospitalized than patients residing in counties with a poverty rate within 1 standard deviation of the mean poverty rate for the United States. Therefore, our analysis demonstrates that the number of hospitalizations in a county is also influenced by the economic prosperity of its surroundings. The reasons for this association are not immediately clear. Nevertheless, these results will contribute to the growing body of disparities research and aid in the identification of geographic areas at increased risk for poor health outcomes post renal transplantation. Further research is required in order to verify the association between neighborhood poverty and hospital readmission post-transplant. Replication should be conducted for a follow up period longer than 1.5 years and at more granular levels of geography, such as the census tract given the variability possible with zip codes.

Appendices

Exclusion flow-chart



		D STANI the inter term			UCED M rop Educ		REDUCED MODEL 2: Drop Cold Ischemia Time		
	Odds Ratio	Lower 95% CI	Upper 95% CI	Odds Ratio	Lower 95% CI	Upper 95% CI	Odds Ratio	Lower 95% CI	Upper 95% CI
MAIN EFFECTS									
Spatial Topography of Poverty (Ref = Other)									
Low poverty (concentrated)	0.98	0.88	1.10	0.99	0.89	1.10	0.99	0.89	1.10
Low poverty (spatial outlier)	1.13	1.01	1.28	1.14	1.01	1.28	1.14	1.01	1.28
High poverty (concentrated)	1.12	1.05	1.21	1.13	1.05	1.21	1.12	1.05	1.20
High poverty (spatial outlier)	0.99	0.87	1.13	0.99	0.87	1.13	0.99	0.87	1.13
COVARIATES									
Race (Ref=White)									
Black	1.057	0.978	1.142	1.062	0.983	1.147	1.063	0.984	1.148
Hispanic	0.827	0.747	0.916	0.834	0.757	0.92	0.834	0.757	0.919
Asian	0.75	0.64	0.86	0.74	0.64	0.86	0.739	0.639	0.855
American Indian/Alaskan Native	0.94	0.69	1.29	0.95	0.70	1.31	0.95	0.694	1.3
Pacific Islander	0.82	0.53	1.27	0.82	0.53	1.27	0.82	0.528	1.273
Multiracial	0.67	0.46	0.99	0.68	0.46	1.00	0.68	0.46	1.00
Sex (Ref = Female)									
Male	0.92	0.86	0.98	0.92	0.86	0.97	0.92	0.86	0.97
Age (Ref = <30)									
30 to 39	0.86	0.76	0.97	0.85	0.75	0.97	0.85	0.75	0.97
40 to 49	0.86	0.765	0.968	0.853	0.758	0.96	0.855	0.76	0.962
50 to 59	0.86	0.77	0.97	0.85	0.76	0.96	0.85	0.76	0.96
60 to 69	0.827	0.73	0.936	0.819	0.724	0.926	0.822	0.726	0.929
>=70	0.93	0.79	1.10	0.92	0.78	1.08	0.921	0.781	1.086
BMI ($Ref = <18.5$)									
18.5 to 24.9	0.98	0.81	1.18	0.98	0.81	1.19	0.98	0.81	1.19

25 to 29.9	0.96	0.79	1.16	0.96	0.79	1.17	0.961	0.791	1.167
30 to 39.9	1.03	0.84	1.25	1.03	0.85	1.25	1.03	0.85	1.25
>=40	1.28	0.97	1.70	1.29	0.97	1.70	1.286	0.972	1.702
Missing	0.767	0.624	0.942	0.771	0.628	0.947	0.771	0.628	0.947
Donor Type (Ref = Living Donor)									
Deceased	1.02	0.93	1.13	1.03	0.93	1.13	1.12	1.04	1.20
Deceased - Expanded Criteria	1.39	1.22	1.58	1.40	1.22	1.59	1.529	1.367	1.712
HLA Match Level (Ref = 0)									
One	0.89	0.81	0.97	0.89	0.81	0.97	0.89	0.81	0.97
Two	0.90	0.82	1.00	0.91	0.82	1.00	0.906	0.82	1.001
Three	0.89	0.80	0.98	0.89	0.81	0.98	0.89	0.81	0.99
Four	0.775	0.678	0.887	0.78	0.682	0.891	0.783	0.685	0.894
Five	0.69	0.60	0.81	0.70	0.60	0.81	0.70	0.61	0.82
Six	0.66	0.56	0.78	0.66	0.56	0.78	0.67	0.57	0.79
Missing	0.871	0.521	1.454	0.87	0.521	1.452	0.864	0.518	1.442
Diabetes (Ref = No)									
Yes	1.30	1.21	1.39	1.30	1.21	1.39	1.30	1.22	1.39
Missing	1.35	1.07	1.71	1.34	1.06	1.69	1.349	1.067	1.706
Hypertension (Ref = No)									
Yes	1.15	1.05	1.25	1.15	1.05	1.25	1.143	1.051	1.244
Missing	1.27	1.07	1.51	1.26	1.06	1.50	1.26	1.06	1.50
Education (Ref = None)									
Grade School (0-8)	1.11	0.74	1.68						
High School (9-12) or GED	1.14	0.77	1.69						
College/Technical School	1.10	0.74	1.64						
Associate/Bachelor Degree	1.02	0.682	1.525						
Post-College Graduate Degree	1.038	0.686	1.57						
Missing	1.079	0.724	1.609						
Primary Payment (Ref = Private Insurance)									
Public Insurance	1.201	1.124	1.282	1.21	1.14	1.29	1.21	1.14	1.30
Other	0.626	0.279	1.405	0.63	0.28	1.40	0.636	0.284	1.427
Serum Albumin (Ref = <= 3.5)									
> 3.5	0.837	0.771	0.908	0.84	0.77	0.91	0.84	0.77	0.91

Missing	0.796	0.725	0.874	0.797	0.726	0.874	0.801	0.73	0.879
Cold Ischemia Time (Ref = 0-10)									
11-20	1.154	1.041	1.279	1.155	1.042	1.28			
21-30	1.138	1.017	1.273	1.139	1.018	1.274			
>30	1.205	1.021	1.422	1.201	1.018	1.417			
Missing	1.056	0.972	1.146	1.055	0.971	1.145			